Xeris Biopharma Holdings (XERS) Assets (2020 - 2026)

Xeris Biopharma Holdings has reported Assets for 7 years, with the latest figure at $392.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 24.27% year-over-year to $392.0 million; the trailing twelve-month figure through Mar 2026 stood at $392.0 million (up 24.27% YoY), and the FY2025 full-year result was $383.5 million, up 18.72% from the prior year.
• Assets for Q1 2026 stood at $392.0 million, up from $383.5 million in the prior quarter.
• The five-year high for Assets was $392.0 million in Q1 2026, with the low at $303.0 million in Q3 2022.
• Historically, Assets has averaged $336.0 million across 5 years, with a median of $328.8 million in 2023.
• Annual changes were most pronounced in 2022 — Assets soared 130.85% — and 2023, when it declined 6.36%.
• Xeris Biopharma Holdings' Assets stood at $344.5 million in 2022, then decreased by 6.36% to $322.6 million in 2023, then climbed by 0.14% to $323.1 million in 2024, then climbed by 18.72% to $383.5 million in 2025, then grew by 2.21% to $392.0 million in 2026.
• The last three Assets figures came in at $392.0 million (Q1 2026), $383.5 million (Q4 2025), and $370.2 million (Q3 2025), per Business Quant data.